{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:34Z","timestamp":1790963614687,"version":"4.1.0"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene-engineered T cell therapies are soon to be United States Food and Drug Administration (FDA) approved for at least two types of B cell malignancies in pediatric and adult patients, in the form of CD19 targeted chimeric antigen receptor T (CAR T) cell therapy. This represents a triumph of a true bench to bedside clinical translation of a therapy that was conceived of in the early 1990s. Clinical results have demonstrated efficacious responses in patients with the CD19 positive diseases B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. However, significant challenges have emerged, including worrisome immune-related toxicities, therapy resistance, and understanding how to administer CD19 CAR T cells in clinical practice. Although much remains to be learned, pioneering clinical trials have led to foundational insights about the clinical translation of this novel therapy. Here, we review the \u201clessons learned\u201d from the pre-clinical and human experience with CAR T cell therapy.<\/jats:p>","DOI":"10.1002\/stem.2715","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T07:56:39Z","timestamp":1507708599000},"page":"36-44","source":"Crossref","is-referenced-by-count":56,"title":["Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies"],"prefix":"10.1093","volume":"36","author":[{"given":"Michael D.","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"},{"name":"Department of Oncologic Sciences, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"},{"name":"Department of Oncologic Sciences, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"2022022511591800400_stem2715-bib-0001","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022022511591800400_stem2715-bib-0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022022511591800400_stem2715-bib-0003","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"2022022511591800400_stem2715-bib-0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2022022511591800400_stem2715-bib-0006","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0007","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"2022022511591800400_stem2715-bib-0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"2022022511591800400_stem2715-bib-0009","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"2022022511591800400_stem2715-bib-0010","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"2022022511591800400_stem2715-bib-0011","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"2022022511591800400_stem2715-bib-0012","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0013","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/imt.13.54","article-title":"Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer","volume":"5","author":"Hombach","year":"2013","journal-title":"Immunotherapy"},{"key":"2022022511591800400_stem2715-bib-0014","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"2022022511591800400_stem2715-bib-0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"2022022511591800400_stem2715-bib-0016","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"2022022511591800400_stem2715-bib-0017","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"2022022511591800400_stem2715-bib-0018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"2022022511591800400_stem2715-bib-0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"2022022511591800400_stem2715-bib-0020","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0021","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0022","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0023","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"2022022511591800400_stem2715-bib-0024","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0025","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2022022511591800400_stem2715-bib-0026","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Investig"},{"key":"2022022511591800400_stem2715-bib-0027","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"2022022511591800400_stem2715-bib-0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022022511591800400_stem2715-bib-0029","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Investig"},{"key":"2022022511591800400_stem2715-bib-0030","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022022511591800400_stem2715-bib-0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: Lessons learned from targeting of CD19 in B-cell malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"2022022511591800400_stem2715-bib-0032","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2022022511591800400_stem2715-bib-0033","doi-asserted-by":"crossref","first-page":"CT078","DOI":"10.1158\/1538-7445.AM2017-CT078","article-title":"Abstract CT078: Impact of disease burden and transplant on long-term survival after CD19 CAR therapy in adults with relapsed B-cell acute lymphoblastic leukemia","volume":"77","author":"Park","year":"2017","journal-title":"Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0034","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor\u2013modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2022022511591800400_stem2715-bib-0036","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"2022022511591800400_stem2715-bib-0037","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0038","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022022511591800400_stem2715-bib-0039","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2017-CT019","article-title":"Abstract CT019: Primary results from ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"77","author":"Locke","year":"2017","journal-title":"Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0040","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022022511591800400_stem2715-bib-0041","doi-asserted-by":"crossref","first-page":"CT020","DOI":"10.1158\/1538-7445.AM2017-CT020","article-title":"Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19)","volume":"77","author":"Locke","year":"2017","journal-title":"Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0042","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2017.35.15_suppl.7024","article-title":"Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19\u201328z CAR T cells in adult patients with relapsed B-ALL","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0043","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2017.35.15_suppl.3019","article-title":"Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R\/R B-ALL) treated with CD19 CAR T cells","volume":"35","author":"Santomasso","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0044","first-page":"S263","article-title":"Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL): Update to the interim analysis","volume":"17","author":"Buechner","year":"2017","journal-title":"Haematologica"},{"key":"2022022511591800400_stem2715-bib-0045","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2022022511591800400_stem2715-bib-0046","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022022511591800400_stem2715-bib-0047","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2016.34.15_suppl.3007","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0048","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","article-title":"Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)","volume":"35","author":"Galon","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0049","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14712598.2017.1322953","article-title":"Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy","volume":"17","author":"Locke","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2022022511591800400_stem2715-bib-0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2017.01.010","article-title":"CD19, from bench to bedside","volume":"183","author":"Li","year":"2017","journal-title":"Immunol Lett"},{"key":"2022022511591800400_stem2715-bib-0051","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"2022022511591800400_stem2715-bib-0052","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: A CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2022022511591800400_stem2715-bib-0053","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"Gokbuget","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2022022511591800400_stem2715-bib-0054","first-page":"326","article-title":"Appropriate management of molecular subtypes of diffuse large B-cell lymphoma","volume":"28","author":"Dunleavy","year":"2014","journal-title":"Oncology"},{"key":"2022022511591800400_stem2715-bib-0055","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"key":"2022022511591800400_stem2715-bib-0056","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2017.35.15_suppl.3023","article-title":"Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)","volume":"35","author":"Locke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0057","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2437_127","article-title":"High CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T product JCAR017 (TRANSCEND NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"Hematol Oncol"},{"key":"2022022511591800400_stem2715-bib-0058","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0059","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nbt0117-6b","article-title":"CAR-T's forge ahead, despite Juno deaths","volume":"35","author":"DeFrancesco","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2022022511591800400_stem2715-bib-0061","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0062","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B cell lymphoma (DLBCL) - An interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"key":"2022022511591800400_stem2715-bib-0063","author":"Childhood acute lymphoblastic leukemia treatment (PDQ(R))","year":"2002"},{"key":"2022022511591800400_stem2715-bib-0064","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11899-017-0371-4","article-title":"Who should receive a transplant for acute lymphoblastic leukaemia?","volume":"12","author":"Dhawan","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2022022511591800400_stem2715-bib-0066","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0067","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0068","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2016.34.15_suppl.7003","article-title":"Impact of disease burden on long-term outcome of 19\u201328z CAR modified T cells in adult patients with relapsed B-ALL","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0069","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0070","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Investig"},{"key":"2022022511591800400_stem2715-bib-0071","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/JCO.2017.35.15_suppl.3024","article-title":"Updated results from ZUMA-3, a phase 1\/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL)","volume":"35","author":"Shah","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0072","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.hoc.2016.07.004","article-title":"Management of relapsed diffuse large B-cell lymphoma","volume":"30","author":"Crump","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022022511591800400_stem2715-bib-0073","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0074","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0075","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0076","year":"2017"},{"key":"2022022511591800400_stem2715-bib-0077","doi-asserted-by":"crossref","first-page":"945TiP","DOI":"10.1093\/annonc\/mdw375.40","article-title":"ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed\/refractory Mantle cell lymphoma (R\/R MCL)","volume":"27","author":"Wang","year":"2016","journal-title":"Ann Oncol"},{"key":"2022022511591800400_stem2715-bib-0078","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"2022022511591800400_stem2715-bib-0079","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"2022022511591800400_stem2715-bib-0080","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"key":"2022022511591800400_stem2715-bib-0081","article-title":"Treatment of Del17p and\/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies","author":"Rafei","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2022022511591800400_stem2715-bib-0082","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL","volume":"34","author":"Porter","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0083","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2017.35.15_suppl.7509","article-title":"CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL","volume":"35","author":"Gill","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0084","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0085","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0086","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/1538-7445.AM2017-2990","article-title":"Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin's lymphoma","volume":"77","author":"Rossi","year":"2017","journal-title":"Cancer Res"},{"key":"2022022511591800400_stem2715-bib-0087","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0088","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0089","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0796-z","article-title":"Anti-PD-1 antibodies as a therapeutic strategy in classical hodgkin lymphoma","author":"Jain","year":"2017","journal-title":"Drugs"},{"key":"2022022511591800400_stem2715-bib-0090","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","article-title":"CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia","volume":"8","author":"Davila","year":"2013","journal-title":"PLoS One"},{"key":"2022022511591800400_stem2715-bib-0091","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0092","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0093","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0094","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2017.35.15_suppl.3020","article-title":"Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0095","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022022511591800400_stem2715-bib-0096","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2017.35.15_suppl.7512","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)","volume":"35","author":"Locke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022511591800400_stem2715-bib-0097","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V128.22.586.586","article-title":"Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2022022511591800400_stem2715-bib-0098","year":"2017"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.2715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.2715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.2715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/36\/1\/36\/42606805\/stmcls_36_1_36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/36\/1\/36\/42606805\/stmcls_36_1_36.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T23:26:55Z","timestamp":1693092415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/36\/1\/36\/6453354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,25]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.2715","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,1]]},"published":{"date-parts":[[2017,10,25]]}}}